William Blair Forecasts Agenus’ Q1 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at William Blair lifted their Q1 2025 earnings per share (EPS) estimates for shares of Agenus in a research note issued on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the biotechnology company will post earnings per share of ($1.17) for the quarter, up from their previous forecast of ($1.31). The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($2.58) EPS and FY2027 earnings at ($2.51) EPS.

Several other equities analysts also recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Wednesday. Robert W. Baird dropped their price objective on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.75.

Agenus Price Performance

NASDAQ AGEN opened at $1.86 on Friday. Agenus has a 1-year low of $1.65 and a 1-year high of $19.69. The company has a market capitalization of $43.63 million, a P/E ratio of -0.17 and a beta of 1.23. The business has a 50 day moving average price of $3.17 and a 200 day moving average price of $3.78.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently made changes to their positions in AGEN. B. Riley Financial Inc. purchased a new stake in shares of Agenus in the fourth quarter valued at $2,074,000. Gilead Sciences Inc. purchased a new stake in shares of Agenus in the fourth quarter valued at $635,000. Walleye Capital LLC purchased a new stake in shares of Agenus in the third quarter valued at $1,003,000. Jane Street Group LLC grew its position in shares of Agenus by 97.6% in the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after purchasing an additional 52,215 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 51,566 shares during the period. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.